- Telix Pharmaceuticals (TLX) has first patient dosed in its prostate-specific membrane antigen
- Telix’s ProstACT study program is evaluating the efficacy of Telix’s lutetium-177 (177Lu)-labelled therapeutic antibodies in all stages of prostate cancer
- The first patient, dosed at Princess Alexandra Hospital in Brisbane, Queensland
- Along with ProstACT TARGET, the program will inform clinical and commercialisation strategies for the TLX591 therapeutic candidate
- Proceeds from the recent capital raise will be applied to the completion of the ProstACT studies
- Telix was trading at $6.62 at market close on January 25
Telix Pharmaceuticals’ (TLX) first patient has been dosed in its prostate-specific membrane antigen (PSMA) targeting ‘ProstACT’ therapeutic program.
This program explores the TLX591 in areas of unmet medical need across the full prostate cancer treatment journey.
Telix’s ProstACT study program is evaluating the efficacy of Telix’s lutetium-177 (177Lu)-labelled therapeutic antibodies in all stages of prostate cancer, from the first recurrence to advanced metastatic disease (known as metastatic castrate-resistant prostate cancer, or mCRPC).
The first patient, dosed at Princess Alexandra Hospital in Brisbane, Queensland, was treated as part of the ProstACT SELECT clinical trial, a Phase I radiogenomics study running concurrently to the pivotal Phase III study, ProstACT GLOBAL.
The goal of ProstACT SELECT is to compare 68Ga-PSMA (gallium-based imaging) and 177Lu-PSMA (lutetium-based therapy), specifically exploring the biodistribution and tumour uptake of small molecule and antibody-based targeting in men with PSMA-expressing mCRPC.
Demonstrating the “theranostic” approach, the study is designed to inform optimal patient selection for 177Lu antibody therapy, with the goal of enabling indication expansion for Telix’s PSMA therapeutic portfolio.
ProstACT SELECT is a multi-centre study and will enrol up to 50 patients and is expected to take approximately 12 months to complete.
“PSMA-targeting is widely considered to be the vanguard of prostate cancer treatment and we are therefore excited to have dosed a first patient in this important series of studies of Telix’s lead candidate for prostate cancer therapy,” Princess Alexandra Hospital, Professor Kenneth O’Byrne said.
“The ProstACT study builds on an already significant body of clinical data for TLX591, which has potential to transform patient outcomes across the full prostate cancer treatment journey.”
Along with ProstACT TARGET, the third study in the program to run concurrently to the SELECT and GLOBAL studies, the program will inform its clinical and commercialisation strategies for the TLX591 therapeutic candidate and generate multiple opportunities for near-term data readouts throughout the program duration.
Proceeds from the recent capital raise will be applied to the completion of the ProstACT studies.
Telix was trading at $6.62 at market close on January 25.